| 徐中华,罗薇薇,黄苗苗,等.基于公共数据库及生物信息学分析转铁蛋白受体对宫颈癌预后和免疫应答的预测价值[J].安徽医药,2026,30(9):1794-1800. |
| 基于公共数据库及生物信息学分析转铁蛋白受体对宫颈癌预后和免疫应答的预测价值 |
| Predictive value of TfR on prognosis and immune response in cervical cancer based on public database and bioinformatics analysis |
| |
| DOI：10.3969/j.issn.1009-6469.2026.09.018 |
| 中文关键词: 宫颈肿瘤 转铁蛋白受体 生物标志物 预后 生物信息学 |
| 英文关键词: Uterine cervical neoplasms Transferrin receptor Biomarkers Prognosis Bioinformatics |
| 基金项目:安徽省高校自然科学研究重点项目( 2023AH053287) |
| 作者 | 单位 | E-mail | | 徐中华 | 安徽医科大学第一附属医院,科研实验中心,安徽合肥 230022
安徽医科大学第一附属医院,妇产科,安徽合肥 230022 | | | 罗薇薇 | 安徽医科大学第一附属医院,放疗科,安徽合肥 230022
安徽医科大学,生育障碍与妇产疾病研究安徽省重点实验室,安徽合肥 230032
安徽医科大学,安徽省生命资源保存与人工器官工程技术研究中心,安徽合肥 230032
安徽医科大学,安徽省转化医学研究院,安徽合肥 230032 | | | 黄苗苗 | 安徽医科大学第一附属医院,妇产科,安徽合肥 230022
安徽医科大学,国家卫生健康委配子及生殖道异常研究重点实验室,安徽合肥 230032
生命资源保存与人工器官教育部工程研究中心,安徽合肥 230032
安徽医科大学,出生人口健康教育部重点实验室,安徽合肥 230032 | | | 杨文娟 | 安徽医科大学第一附属医院,妇产科,安徽合肥 230022
安徽医科大学,国家卫生健康委配子及生殖道异常研究重点实验室,安徽合肥 230032
生命资源保存与人工器官教育部工程研究中心,安徽合肥 230032
安徽医科大学,出生人口健康教育部重点实验室,安徽合肥 230032 | | | 王影 | 安徽医科大学第一附属医院,妇产科,安徽合肥 230022
安徽医科大学,生育障碍与妇产疾病研究安徽省重点实验室,安徽合肥 230032
安徽医科大学,安徽省生命资源保存与人工器官工程技术研究中心,安徽合肥 230032
安徽医科大学,安徽省转化医学研究院,安徽合肥 230032 | | | 吴荣 | 安徽医科大学第一附属医院,妇产科,安徽合肥 230022
安徽医科大学,国家卫生健康委配子及生殖道异常研究重点实验室,安徽合肥 230032
生命资源保存与人工器官教育部工程研究中心,安徽合肥 230032
安徽医科大学,出生人口健康教育部重点实验室,安徽合肥 230032 | | | 吴潇 | 安徽医科大学第一附属医院,妇产科,安徽合肥 230022
安徽医科大学,生育障碍与妇产疾病研究安徽省重点实验室,安徽合肥 230032
安徽医科大学,安徽省生命资源保存与人工器官工程技术研究中心,安徽合肥 230032
安徽医科大学,安徽省转化医学研究院,安徽合肥 230032 | | | 章龙玉 | 安徽医科大学第一附属医院,妇产科,安徽合肥 230022
安徽医科大学,生育障碍与妇产疾病研究安徽省重点实验室,安徽合肥 230032
安徽医科大学,安徽省生命资源保存与人工器官工程技术研究中心,安徽合肥 230032
安徽医科大学,安徽省转化医学研究院,安徽合肥 230032 | | | 许孝凤 | 安徽医科大学第一附属医院,妇产科,安徽合肥 230022
安徽医科大学,国家卫生健康委配子及生殖道异常研究重点实验室,安徽合肥 230032
生命资源保存与人工器官教育部工程研究中心,安徽合肥 230032
安徽医科大学,出生人口健康教育部重点实验室,安徽合肥 230032 | | | 周曙光 | 合肥市妇幼保健院妇产科,安徽合肥 230001 | | | 胡晶晶 | 安徽医科大学第一附属医院,妇产科,安徽合肥 230022
安徽医科大学,国家卫生健康委配子及生殖道异常研究重点实验室,安徽合肥 230032
生命资源保存与人工器官教育部工程研究中心,安徽合肥 230032
安徽医科大学,出生人口健康教育部重点实验室,安徽合肥 230032 | janejj55@126.com |
|
| 摘要点击次数: 350 |
| 全文下载次数: 40 |
| 中文摘要: |
| 目的基于公共数据库及生物信息学分析转铁蛋白受体(TfR)对宫颈癌预后和免疫应答的预测价值。方法 2024年 2— 10月，基于癌症基因组图谱( TCGA)、基因表达综合( GEO)和人类蛋白图谱(HPA)数据库分析 TfR在宫颈癌中的表达特征。采用 Kaplan-Meier生存曲线、单因素及多因素 Cox评估 TfR对肿瘤病人预后价值。使用基因本体论( GO)/京都基因和基因组数据库( KEGG)/基因集富集分析( GSEA)鉴定与 TfR相关的信号通路，采用肿瘤免疫功能障碍与排斥( TIDE)评分和免疫表型评分 |
| 英文摘要: |
| Objective To analyze the predictive value of transferrin receptor (TfR) on the prognosis and immune response of cervicalcancer based on public database and bioinformatics analysis.Methods From February to October 2024, the expression characteristicsof TfR in cervical cancer were analyzed based on The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and Human Pro.tein Atlas (HPA) databases. Kaplan-Meier survival curve, univariate and multivariate Cox regression analyses were performed to evalu.ate the prognostic value of TfR in patients with cervical cancer. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes(KEGG) and gene set enrichment analysis (GSEA) were applied to identify TfR-related signaling pathways. Tumor immune dysfunctionand exclusion (TIDE) score and immunophenoscore (IPS) were adopted to assess the correlation between TfR expression and immuno.therapy efficacy. Results A total of the TCGA dataset and 3 independent validation cohorts (GSE7803, GSE9750 and GSE63514)were included. The results showed that both mRNA and protein levels of TfR were significantly higher in cervical cancer tissues thanthose in normal cervical tissues. In the GSE7803 cohort, TfR expression in the normal group and in the tumor group was 3.81±0.04 and3.93±0.10, respectively; in the GSE9750 cohort, it was 10.28±0.59 and 11.44±1.14 respectively; in the GSE63514 cohort, it was 3.88±0.10 and 3.96±0.16 respectively. Patients with high TfR expression had shorter overall survival and progression-free survival than those with low TfR expression (all P<0.05). Clinical correlation analysis confirmed that TfR expression was significantly higher in T3+T4stage patients than that in T1+T2 stage patients. Differentially expressed genes associated with TfR were mainly enriched in signalingpathways including carbon metabolism, glycolysis, hypoxia-inducible factor-1 (HIF-1) pathway and ferroptosis. Meanwhile, aberrantTfR expression was closely associated with immune microenvironment imbalance in cervical cancer. Meanwhile, the abnormal expres.sion of TfR in cervical cancer was closely related to the disorder of immune microenvironment, and in tumors with high expression ofTfR, the infiltration of quiescence CD4+ memory T cells, eosinophils and quiescence dendritic cells increased. The infiltration of regula. tory T (Treg) cells and CD8+ T cells decreased. Furthermore, TfR expression was negatively correlated with immune checkpoint mole.cules, including programmed death-1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), lymphocyte activation gene 3 (LAG-3) and T cell immunoglobulin and ITIM domain (TIGIT). IPS and TIDE analyses further verified that TfR expression was nega.tively correlated with multiple immune-related indicators, and the immune exclusion score was elevated in the high expression group,indicating that high TfR expression might be linked to poor response to immunotherapy.Conclusions TfR is significantly upregulatedin cervical cancer and acts as an independent risk factor for poor prognosis. It may participate in cervical cancer progression by regulat.ing tumor metabolic pathways and remodeling the suppressive tumor immune microenvironment, and can serve as a potential biomarkerfor prognostic evaluation and therapeutic target selection of cervical cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
